Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million.

Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of 10.63%. This comes even as the 90 day share price return of 34.14% and 1 year total shareholder return of 86.19% point to momentum that has built over a longer stretch, alongside a 3 year total shareholder return of 87.40% and a broadly flat 5 year total shareholder return of 0.05%.

If this kind of biotech news has your attention, it could be a good moment to scan other healthcare stocks that might benefit from similar clinical or revenue catalysts.

With Rigel Pharmaceuticals trading at US$37.48 versus an analyst price target of US$51.60 and an estimated intrinsic value gap, is the recent pullback a chance to enter, or is the market already pricing in expectations for future growth?

Most Popular Narrative: 26.8% Undervalued

The most followed narrative currently sees Rigel Pharmaceuticals’ fair value at US$51.20 versus the last close at US$37.48, putting a material gap between the market price and that fair value estimate.

The Fair Value Estimate has risen slightly from US$49.60 to US$51.20, reflecting updated model inputs.

The Discount Rate has edged up from 7.12% to 7.14%, representing a small change in the assumed risk profile used in the valuation work.

Curious what kind of revenue path and profit margins support that higher fair value, even with a lower future P/E multiple baked in, and why analysts still see room above the current price despite more conservative assumptions on earnings power and valuation? The full narrative walks through those moving parts in detail.

Result: Fair Value of $51.20 (UNDERVALUED)

However, the story could shift quickly if R289 or olutasidenib stumble in trials, or if reliance on a few key drugs makes revenue more fragile.

Build Your Own Rigel Pharmaceuticals Narrative

If you see the story differently, or simply prefer to work through the numbers yourself, you can build a custom view in just a few minutes, Do it your way.

A great starting point for your Rigel Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Rigel has sharpened your interest, do not stop here. Use the Simply Wall St Screener to spot other opportunities before the crowd moves on.

• Identify high potential value opportunities by scanning these 862 undervalued stocks based on cash flows that currently trade below their estimated cash flow driven fair values.
• Explore structural themes in technology by checking out these 24 AI penny stocks that are tied to artificial intelligence adoption across multiple industries.
• Find income focused ideas by reviewing these 12 dividend stocks with yields > 3% that may help you build a portfolio with regular cash returns above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.